Aminopyridine – Multiple Sclerosis

Fampridine is indicated for symptomatic improvement of walking in adults with multiple sclerosis, including relapsing remitting, secondary progressive,  relapsing and primary progressive. Currently there are no other drugs available for this indication.

Fampridine is thought to increase conduction in demyelinated nerves by inhibiting potassium channels. It can be used on its own or with other treatments for multiple sclerosis, including immunomodulatory drugs. This means that it can block the flow of ions in nerve cells, which results in a more effective nerve impulse traveling down toward the muscles. It has been studied most extensively in MS and other demyelinating neurological disorders, however its exact mechanism of action of this drug remains uncertain. 4-AP has been used for many years to treat symptoms associated with MS. The poor nerve impulses in patients with MS is the cause of most of the symptoms of the disease including visual deficits, weakness, numbness, paralysis and other sensory disturbances. (Compston and Coles, 2008; Smith and McDonald, 1999; McDonald, 1974), Weakness and fatigue are probably the most common problems people who suffer from Multiple Sclerosis (MS) face on a daily basis.


Before you take any medication inform your doctor and our pharmacists of any other medical conditions, including other prescription and non-prescription medicines, vitamins and herbal supplements. It is important that you understand and know your medications, keep a list of them and show it to your doctor and our Healthcare pharmacists prior to commencing any new medication. If in doubt please ask and we will explain your medications to you.


Before commencing treatment and  or obtaining a repeat of 4-AP, we recommend you read this Consumer Medication Information (CMI). Please visit this page to download the information – Medicine Information.


We compound two versions of 4-A, an immediate release or standard release formulation and a slow/sustained release also known as controlled release capsules.

For both versions we recommend a staged dosing procedure, to allow the body to come a custom to the new medication we recommend that a single daily dose betaken for two to three days, then increase to two capsules daily.

Immediate Release. ( 5mg and 10mg capsules)

Slow Release (SR) or Controlled Release (CR) 10mg capsules

Note: Your doctor will decided on the strength.

References *†

  1. Goodman AD, Brown TR,Krupp LB, Schapiro RT, Schw
  2. Medscape